Over the last few decades, novel drug classes such as immunomodulators (e.g., lenalidomide), proteasome inhibitors (e.g., bortezomib), histone deacetylase inhibitors (e.g., panobinostat), and monoclonal antibodies (mAbs) (e.g., daratumumab [anti-CD38]) have significantly improved the response rates and overall survival for MM patients (5, 6). This evidence concerns the gene CD38 and Miyoshi myopathy.